Abstract 2145
Background
The pathological classification of pancreatic neuroendocrine neoplasms (PanNENs) has been revised based on the World Health Organization (WHO) 2017 classification. Well-differentiated PanNENs were previously classified as G1, G2, or G3 according to the Ki-67 labeling index (LI), which shows the cell proliferation ability. Although the Ki67 LI cut-off for G1 and G2 was changed from ≤2% to < 3% from WHO 2010 to 2017, there are few reports on the impact of G2 tumor malignancy associated with this change.
Methods
Patients with PanNENs G1/G2 classified by WHO 2017 Ki-67 LI cut-off who underwent pancreatic resection at our institution between July 1987 and March 2019 were retrospectively analyzed. We excluded patients with synchronous distant metastasis at the time of diagnosis. Their clinicopathological variables were analyzed.
Results
Sixty-two patients (median age: 58 years; range: 18–84 years) were examined. The G1/G2 groups comprised 40/22 and 48/14 patients based on WHO 2010 and 2017 classifications, respectively. Eight patients were reclassified from G2 to G1, two of which were T2 or more based on TNM classification; one patient had lymph node metastasis positivity, and all patients survived without recurrence. Disease recurrence occurred in 4/4 G1/G2 patients according to both WHO 2010 and 2017. G2 patients had shorter 5- and 10-year disease-free survivals (DFSs) than those of G1 patients based on WHO 2010 (90.9% and 90.9% vs. 84.5% and 70.4%, p = 0.179) and significantly shorter DFS based on WHO 2017 (91.9% and 91.9% vs. 78.6% and 58.9%, p = 0.036). The Ki-67 LI cut-off by ROC analysis was 3%, supporting the WHO 2017 classification. In multivariate analysis for DFS, tumor size >25 mm and vascular invasion positivity, but not G2, were risk factors for recurrence. The high-risk group with these factors had significantly worse 5- and 10-year disease-specific survivals (DSSs) compared to the low-risk group (100% and 100% vs. 90.9% and 68.2%, p = 0.045).
Conclusions
Revision of the Ki-67 LI cut-off for PanNENs G1/G2 based on WHO 2017 may be appropriate but G2 is not a risk factor for DFS. Tumor size >25 mm and vascular invasion positivity are potential risk factors. High-risk patients should be closely monitored during follow-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3911 - Defining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy
Presenter: Marcin Kubeczko
Session: Poster Display session 2
Resources:
Abstract
1849 - Effect of thioredoxin 1 quantity detection to complement the mammography in breast cancer diagnosis
Presenter: Younju Lee
Session: Poster Display session 2
Resources:
Abstract
2221 - Identification of ultralow risk breast cancer patients (probable overdiagnosis)
Presenter: Salvador Gamez Casado
Session: Poster Display session 2
Resources:
Abstract
5291 - Prevalence of Vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward.
Presenter: Warner Finstad
Session: Poster Display session 2
Resources:
Abstract
4247 - Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
Presenter: Arran Turnbull
Session: Poster Display session 2
Resources:
Abstract
568 - Second primary malignancies in patients with breast cancer.
Presenter: Carlos Erasun Lecuona
Session: Poster Display session 2
Resources:
Abstract
1428 - Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) Breast Cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
Presenter: Laura Biganzoli
Session: Poster Display session 2
Resources:
Abstract
1479 - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
1481 - A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
4334 - ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer.
Presenter: Michail Ignatiadis
Session: Poster Display session 2
Resources:
Abstract